After Pfizer buyout, VCs back team with $55M for next specialty pharma

Pfizer, NEA-backed rare disease startup bumps up Series A to $42M

Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII

Bankrupt biotech Bind eyes $20M sale to Pfizer

Pfizer, German Merck start first-ever PhIII PD-L1 combo trial for ovarian cancer

Medivation plans a bidding war as it rejects Sanofi’s sweetened bid

Parexel predicts strong growth amid ‘paradigm shifts’ in biopharma

Israeli upstart Vidac raises $9M for cancer, skin condition trials push

Pfizer aces another pair of PCSK9 inhibitor trials

Former Pfizer exec invests in $10M Series A for cancer startup